Semaglutide
medicationA GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
Guide
As listed on October 7, 2026, NovoCare Pharmacy self-pay prices are $349 a month for the Wegovy pen, or $199 for a new patient’s first two fills, and $149 to $299 a month for the Wegovy pill. The list price is $1,349.02 a package. With commercial coverage, the savings offer can bring it to $25.

As listed on October 7, 2026, NovoCare Pharmacy self-pay is $349 a month for the standard Wegovy pen strengths. Patients new to the offer pay $199 a month for their first two fills at the two lowest strengths, through December 31, 2026. The highest-strength Wegovy HD pen is $399 a month. NovoCare

NovoCare says its pricing will be updated after December 31, 2026, so check the date on any price you see. NovoCare
| Product | Strength tier | Self-pay price a month |
|---|---|---|
| Wegovy pen | Two lowest strengths, first two fills for new patients | $199 |
| Wegovy pen | All standard strengths after that | $349 |
| Wegovy HD pen | Highest strength | $399 |
| Wegovy pill | Lowest strength | $149 |
| Wegovy pill | Second strength | $199 |
| Wegovy pill | Two highest strengths | $299 |
As listed on October 7, 2026, NovoCare self-pay prices for the Wegovy pill are $149 a month for the lowest strength, $199 for the second, and $299 for the two highest. The pill is FDA-approved for weight management, and the pill vs injection guide compares the two forms. NovoCare

NovoCare gives the list price of the Wegovy pill, pen and HD pen as $1,349.02 a package. Novo Nordisk has announced that the list price falls to $675 a month from January 1, 2027, and says that change does not affect its direct-to-patient self-pay prices. NovoCare

Novo Nordisk described the January 2027 change as a reduction of about 50%. Novo Nordisk (Feb 24, 2026)
Yes. With commercial insurance that covers Wegovy, the savings offer lets eligible patients pay as little as $25, with savings capped at $100 a month. The program is open to people with commercial insurance and to uninsured or self-paying patients. NovoCare
On October 7, 2026, TrumpRx.gov listed the Wegovy pill from $149 a month and the Wegovy pen from $199 a month, for self-pay patients. The pen price applies to the first two monthly fills for new patients, then $349 a month, matching NovoCare. TrumpRx.gov
The TrumpRx home page listed both products against a $1,349 original price. TrumpRx.gov
It is not an equivalent. Compounded semaglutide is not FDA-approved, FDA warns some uses salt forms that are different active ingredients, and with the shortage over FDA says pharmacies should not make copies of approved drugs. FDA
Compare the routes you actually qualify for before the first fill, since prices differ by form, strength and insurance.
Adds Semaglutide to My Journal, with the questions to ask a clinician. It stays in this browser, and nothing on it is a commitment.
Licensed providers that list each one on DiscoverMedica, by name. The full list is on each compound’s page.
Prices as listed by the provider when we checked; they change.
Novo Nordisk’s Wegovy savings offer lets eligible patients with commercial coverage pay as little as $25, with savings capped at $100 a month, as listed on October 7, 2026. Self-pay prices through NovoCare Pharmacy are available to uninsured patients too.
As listed on October 7, 2026, NovoCare self-pay prices are $149 a month for the lowest strength, $199 for the second and $299 for the two highest.
At most strengths, yes, as listed on October 7, 2026: the pill costs $149 to $299 a month through NovoCare self-pay, against $349 a month for standard pen strengths after the new-patient offer.
Novo Nordisk has announced a list price of $675 a month from January 1, 2027, and says self-pay prices are not affected by that change.
Last reviewed October 7, 2026. Every source above was checked on or before that date. Educational information only, not medical advice; it does not replace a conversation with a licensed clinician. DiscoverMedica does not employ clinicians.
A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.